Embecta Corp. (EMBC) fair value analysis
Nasdaq · Updated 2026-10-19
EMBC price how computed
Forward Fair Value verdict
UndervaluedEMBC is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $6.27
- Sector
- Healthcare
- 12-month range
- $2.90–$14.64
- Market cap
- $355M
- From 52-week high
- -57.2%
- Shares outstanding
- 56.7M
- Rank in Healthcare by discount to fair value
- #11 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Embecta Corp. is a healthcare company that manufactures and distributes insulin delivery devices, pen needles, and other injection products used by patients with diabetes. The company operates globally, serving customers across multiple continents through its portfolio of medical devices designed to improve the administration of injectable medications.
EMBC currently ranks #11 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $355M
- P/E (trailing)
- 3x
- Revenue (TTM)
- $1.02B
- Net margin
- 8.6%
- EPS (TTM)
- $2.04
- Gross margin
- 56.4%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- -1.2%
- Shares outstanding
- 56.7M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 69 · neutral
- 50-day average
- $5.43
- 200-day average
- $6.73
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $0.32 per share (4 payments)
- Yield on last price
- 5.10%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-08-27
- Last payment date
- 2026-09-15
Earnings how computed
- Next earnings report
- 2026-11-24
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+115.4%)
2026-03 ▼ miss (-35.7%)
2025-12 ▲ beat (+6.0%)
2025-09 ▲ beat (+8.7%)
2025-06 ▲ beat (+43.6%)
2025-03 ▲ beat (+18.6%)
2024-12 ▲ beat (+47.7%)
2024-09 ▲ beat (+25.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 0 buy · 3 hold · 1 sell (4 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $4
- Target vs last price
- -36.2%
What our data shows for EMBC
- Our model validated 8 trailing price-to-earnings windows for EMBC, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $2.90–$14.64.
- The 14-day relative strength index sits at a neutral 69.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for EMBC
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the EMBC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — EMBC's momentum indicator downgraded from B to none this week, reflecting a loss of positive directional strength. The company's sector discount rank declined to number 19 from number 9, indicating it is now less attractively valued relative to other Healthcare sector peers. Despite these deteriorating technical indicators, EMBC remains classified as undervalued on an absolute basis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is EMBC stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), EMBC is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is EMBC's TickrTrends verdict?
EMBC's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does EMBC compare to other Healthcare stocks?
EMBC ranks #11 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is EMBC overbought or oversold?
EMBC's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does EMBC pay a dividend?
Yes. EMBC paid $0.32 per share over the last twelve months (4 payments), a 5.10% yield on TickrTrends' last price. The last ex-dividend date was 2026-08-27.
When does EMBC report earnings next?
EMBC's next earnings report is scheduled for 2026-11-24, per the published earnings calendar.
Does EMBC usually beat earnings estimates?
Over its last 8 reported quarters EMBC beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about EMBC?
Of 4 analysts covering EMBC, 0 rate it a buy, 3 a hold and 1 a sell - hold-leaning, with a consensus price target of $4 (-36.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
EMBC vs ANIP · EMBC vs COLL · EMBC vs COO · EMBC vs DXCM · EMBC vs HQY